Compounds and methods for treating zinc matrix metalloprotease dependent diseases

A compound of formula II

• wherein:
• R1 is present at m occurrences, m is an integer from 0 to 1, and R1 is C1-C6 alkyl or C—R8;
• R2 is present at n occurrences, n is an integer from 0 to 1, and R2 is selected from a proton, C1-C6 alkyl, C(═O)OR7, alkyl-ORS, C—R8, and alkyl-NR9;
• R3 is selected from a proton, C(═O)OR10, C(═O)OR7, C(═O)NR7, C3-C6 heterocycloalkylaryl, C3-C6 cycloalkenylaryl, C—R8, heteroaryl, and aryl optionally substituted at each carbon atom by halo, OH, OCH3, O-alkyl, amino, substituted amino, —SO2NH2, substituted sulfonamide, —SO2CH3, substituted sulfoxies, CONH2, substituted amido, COCH3, substituted ketones, CHO, cyano, NO2, C(═O)OR10, and C1-C6 alkyl which is further optionally substituted by halo, amino, or hydroxyl;
• R4 is present at p occurrences, p is an integer from 0 to 1, and R4 is C1-C6 alkyl or C—R8;
• R5 is a hydrogen atom, or a bond such that the molecule formed a symmetrical dimer at the disulfide bond, a mixed disulfide with other monosulfide compounds such as ethanethiol, or functional groups such as acetyl to form esters which can be used as prodrugs, H, and —C(═O)R10;
• R6 is present at q occurrences, q is an integer from 0 to 1, and R6 is aryl;
• R7 is selected from C—R8;
• R8 is selected from C3-C6 cycloalkenylaryl, C3-C6 heterocycloalkenylaryl, and aryl optionally substituted by OH, aryl, or ° R10
• R9 is C(═O)OR10;
• R10 is C1-C6 alkyl;
• or
• pharmaceutically acceptable salts and prodrugs thereof.

A compound of formula III

• wherein:
• Y is selected from C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkenylaryl, C3-C6 heterocycloalkenylaryl, C3-C6 cycloalkylaryl, C3-C6 heterocycloalkylaryl, aryl, heteroaryl, C3-C6 heterocycloalkenyl, C3-C6 arylcycloalkylaryl, any of which is optionally substituted at each carbon atom by R1, and wherein when one or more heteroatoms are nitrogen, the nitrogens are each independently unsubstituted or substituted by R2;
• R1 is selected from OH, cyano, SH, halo, alkyl-NR2R3, OR2, aryl, oxo, C—R3, OR3, C2-C6 alkynyl, C3-C6 heterocycloalkenylaryl, C1-C6 alkyl optionally substituted by halo;
• and C3-C6 heterocycloalkenyl which is optionally substituted at each carbon atom by R4;
• R2 is selected from C1-C6 alkyl;
• R3 is selected from a proton, C(═O)OR10, C(═O)OR7, C(═O)NR7, C3-C6 heterocycloalkylaryl, C3-C6 cycloalkenylaryl, C—R8, heteroaryl, and aryl optionally substituted at each carbon atom by halo, OH, OCH3, O-alkyl, amino, substituted amino, —SO2NH2, substituted sulfonamide, —SO2CH3, substituted sulfoxies, CONH2, substituted amido, COCH3, substituted ketones, CHO, cyano, NO2, C(═O)OR10, and C1-C6 alkyl which is further optionally substituted by halo, amino, or hydroxyl;
• R4 is C(═O)OR2;
• R5 is a hydrogen atom, or a bond such that the molecule formed a symmetrical dimer at the disulfide bond, a mixed disulfide with other monosulfide compounds such as ethanethiol, or functional groups such as acetyl to form esters which can be used as prodrugs;
• or
• pharmaceutically acceptable salts and prodrugs thereof.